Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q2 2025 · 10-Q
Revenue$105.56M$105.56M−37.4% vs Q2 2024 Net Income$2.48M$2.48MN/M vs Q2 2024 EPS Diluted$0.22$0.22N/M vs Q2 2024 Gross Profit$76,644,000−37.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,378,000N/M Free Cash Flowderived-$4,756,000N/M Margins · derivedGross margin72.6%−0.6 pt vs Q2 2024
Operating margin-1.0%+3.7 pt vs Q2 2024
Net margin2.3%+7.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 4, 2025 · 35 d after period end